Zhongzhi Pharmaceutical Holdings Limited Statistics
Want to see HK:3737 full AI Analyst Report?
Zhongzhi Pharmaceutical Holdings Limited (3737) Stock Statistics & Valuation Metrics
Total Valuation
Zhongzhi Pharmaceutical Holdings Limited has a market cap or net worth of HKD 567.49M. The enterprise value is HKD 588.70M.
- Market Cap
- HKD 567.49M
- Enterprise Value
- HKD 588.70M
Share Statistics
Zhongzhi Pharmaceutical Holdings Limited has 863,600,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 863,600,000
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Zhongzhi Pharmaceutical Holdings Limited’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 0.34%.
- Return on Equity (ROE)
- 0.02
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 0.34%
- Return on Capital Employed (ROCE)
- 0.00
- Revenue Per Employee
- 801.42K
- Profits Per Employee
- 7,975.092
- Employee Count
- 2,168
- Asset Turnover
- 0.95
- Inventory Turnover
- 2.84
Valuation Ratios
The current PE Ratio of Zhongzhi Pharmaceutical Holdings Limited is 26.70. Zhongzhi Pharmaceutical Holdings Limited’s PEG ratio is -2.85.
- PE Ratio
- 26.70
- PS Ratio
- 0.29
- PB Ratio
- 0.44
- Price to FCF
- 7.53
- Price to Operating Cash Flow
- 5.07
- PEG Ratio
- -2.85
Income Statement
In the last 12 months, Zhongzhi Pharmaceutical Holdings Limited had revenue of 1.74B and earned 17.29M in profits. Earnings per share was 0.02.
- Revenue
- 1.74B
- Gross Profit
- 940.25M
- Operating Income
- 4.93M
- Pretax Income
- 18.99M
- Net Income
- 17.29M
- EBITDA
- 99.81M
- Earnings Per Share (EPS)
- 0.02
Cash Flow
In the last 12 months, operating cash flow was 94.71M and capital expenditures -30.94M, giving a free cash flow of 63.77M billion.
- Operating Cash Flow
- 94.71M
- Free Cash Flow
- 63.77M
- Free Cash Flow per Share
- 0.08
Dividends & Yields
Zhongzhi Pharmaceutical Holdings Limited pays an annual dividend of HKD 0.05, resulting in a dividend yield of 7.46%
- Dividend Per Share
- HKD 0.05
- Dividend Yield
- 7.46%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 13.29%
- Earnings Yield
- 3.67%
Stock Price Statistics
- Beta
- 0.06
- 52-Week Price Change
- 11.67%
- 50-Day Moving Average
- 0.69
- 200-Day Moving Average
- 0.73
- Relative Strength Index (RSI)
- 54.13
- Average Volume (3m)
- 394.63K
Important Dates
Zhongzhi Pharmaceutical Holdings Limited upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- May 23, 2025
Financial Position
Zhongzhi Pharmaceutical Holdings Limited as a current ratio of 1.60, with Debt / Equity ratio of 20.73%
- Current Ratio
- 1.60
- Quick Ratio
- 1.15
- Debt to Market Cap
- 0.46
- Net Debt to EBITDA
- 0.26
- Interest Coverage Ratio
- 0.94
Taxes
In the past 12 months, Zhongzhi Pharmaceutical Holdings Limited has paid 1.28M in taxes.
- Income Tax
- 1.28M
- Effective Tax Rate
- 0.07
Enterprise Valuation
Zhongzhi Pharmaceutical Holdings Limited EV to EBITDA ratio is 3.61, with an EV/FCF ratio of 6.37.
- EV to Sales
- 0.25
- EV to EBITDA
- 3.61
- EV to Free Cash Flow
- 6.37
- EV to Operating Cash Flow
- 4.29
Balance Sheet
Zhongzhi Pharmaceutical Holdings Limited has HKD 185.38M in cash and marketable securities with HKD 87.63M in debt, giving a net cash position of HKD 97.75M billion.
- Cash & Marketable Securities
- HKD 185.38M
- Total Debt
- HKD 87.63M
- Net Cash
- HKD 97.75M
- Net Cash Per Share
- HKD 0.11
- Tangible Book Value Per Share
- HKD 1.30
Margins
Gross margin is 53.18%, with operating margin of 0.96%, and net profit margin of 1.07%.
- Gross Margin
- 53.18%
- Operating Margin
- 0.96%
- Pretax Margin
- 1.94%
- Net Profit Margin
- 1.07%
- EBITDA Margin
- 6.83%
- EBIT Margin
- 0.66%
Analyst Forecast
The average price target for Zhongzhi Pharmaceutical Holdings Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -15.17%
- EPS Growth Forecast
- -11.41%
Scores
- Smart Score
- 6
- AI Score
- 61

